<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Endometrial carcinoma: Clinical features, diagnosis, prognosis, and screening</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Endometrial carcinoma: Clinical features, diagnosis, prognosis, and screening</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Endometrial carcinoma: Clinical features, diagnosis, prognosis, and screening</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Lee-may Chen, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Jonathan S Berek, MD, MMS</a></dd><dt><span> </span>Section Editors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Barbara Goff, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Don S Dizon, MD, FACP</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Alana Chakrabarti, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Sep 15, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1267574"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Uterine cancer is the most common gynecologic malignancy in high-income countries and the second most common in low- and middle-income countries (cervical cancer is more common). Adenocarcinoma of the endometrium (lining of the uterus) is the most common histologic site and type of uterine cancer  (<a class="graphic graphic_picture graphicRef116353" href="/d/graphic/116353.html" rel="external">picture 1</a>). </p><p>Abnormal uterine bleeding is the cardinal symptom of endometrial cancer. A minority of patients present with abnormal findings on cervical cytology. Most patients are diagnosed when disease is still confined to the uterus and thus have a greater than 90 percent five-year survival rate. </p><p>The clinical features, diagnosis, and prognosis of patients with endometrial cancer will be reviewed here. Issues related to screening will also be discussed. Other important issues are discussed in detail separately, including:</p><p class="bulletIndent1"><span class="glyph">●</span>Epidemiology and risk factors (see  <a class="medical medical_review" href="/d/html/3249.html" rel="external">"Endometrial carcinoma: Epidemiology, risk factors, and prevention"</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Histopathology and pathogenesis (see  <a class="medical medical_review" href="/d/html/3192.html" rel="external">"Endometrial cancer: Pathology and classification"</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Staging and surgical treatment (see  <a class="medical medical_review" href="/d/html/3251.html" rel="external">"Endometrial carcinoma: Staging and surgical treatment"</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Medical therapy (see  <a class="medical medical_review" href="/d/html/16917.html" rel="external">"Overview of resectable endometrial carcinoma", section on 'Role of adjuvant therapy'</a> and  <a class="medical medical_review" href="/d/html/3223.html" rel="external">"Treatment of low-risk endometrial cancer"</a> and  <a class="medical medical_review" href="/d/html/16721.html" rel="external">"Adjuvant treatment of high-risk endometrial cancers"</a> and  <a class="medical medical_review" href="/d/html/16741.html" rel="external">"Adjuvant treatment of intermediate-risk endometrial cancer"</a> and  <a class="medical medical_review" href="/d/html/3186.html" rel="external">"Management of locoregional recurrence of endometrial cancer"</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Posttreatment issues and surveillance (see  <a class="medical medical_review" href="/d/html/17006.html" rel="external">"Overview of approach to endometrial cancer survivors"</a>)</p><p></p><p class="headingAnchor" id="H336595"><span class="h1">CLINICAL PRESENTATION</span></p><p class="headingAnchor" id="H281205"><span class="h2">Abnormal uterine bleeding</span><span class="headingEndMark"> — </span>Endometrial carcinoma typically presents with abnormal uterine bleeding (AUB), which is present in 75 to 90 percent of cases [<a href="#rid1">1-3</a>]. The amount of AUB does not correlate well with the risk of endometrial cancer; however, in patients with AUB, age and risk factors affect the likelihood of the disease. (See  <a class="medical medical_review" href="/d/html/3249.html" rel="external">"Endometrial carcinoma: Epidemiology, risk factors, and prevention"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>Most cases of endometrial cancer occur in patients ≥55 years of age. In a meta-analysis of observational studies, the pooled prevalence of postmenopausal bleeding among patients with endometrial cancer was 91 percent (95% CI 87-93), irrespective of tumor stage [<a href="#rid4">4</a>]. The pooled risk of endometrial cancer among patients with postmenopausal bleeding was 9 percent (95% CI 8-11), with estimates varying by use of hormone therapy (risk range 7-12 percent) and geographic region (risk 5 percent in North America to 13 percent in Western Europe). </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The risk of cancer is less in premenopausal patients with AUB, although patients ages 45 to 54 account for 17 percent of endometrial cancer cases and patients ages 35 to 44 account for 5 percent of cases. </p><p></p><p class="bulletIndent2"><span class="glyph">•</span>In patients age 45 to menopause, bleeding may be intermenstrual, frequent (interval between the onset of bleeding episodes is less than 21 days), heavy (total volume of &gt;80 mL), or prolonged (longer than 7 days). In addition, they may have prolonged periods of amenorrhea (six or more months) due to anovulation. </p><p></p><p class="bulletIndent2"><span class="glyph">•</span>In patients younger than age 45, AUB tends to be persistent and occurs in the setting of a history of unopposed estrogen exposure (obesity, chronic anovulation), failed medical management of the bleeding, or in patients at high risk of endometrial cancer (eg, Lynch syndrome)  (<a class="graphic graphic_table graphicRef62089" href="/d/graphic/62089.html" rel="external">table 1</a>). </p><p></p><p>The diagnostic evaluation of patients with AUB, which may lead to a diagnosis of endometrial cancer, is reviewed in detail separately (see  <a class="medical medical_review" href="/d/html/3263.html" rel="external">"Abnormal uterine bleeding in nonpregnant reproductive-age patients: Terminology, evaluation, and approach to diagnosis"</a> and  <a class="medical medical_review" href="/d/html/5421.html" rel="external">"Approach to the patient with postmenopausal uterine bleeding", section on 'Initial evaluation'</a>). The differential diagnosis of AUB is also discussed separately. (See  <a class="medical medical_review" href="/d/html/5440.html" rel="external">"Causes of female genital tract bleeding"</a>.)</p><p class="headingAnchor" id="H281213"><span class="h2">Abnormal cervical cytology</span><span class="headingEndMark"> — </span>Patients with endometrial cancer may present with abnormal cytologic findings on cervical cancer screening. These findings may include endometrial cells (reported in the results in patients ≥40 years of age), atypical glandular cells, or adenocarcinoma (which may be endocervical or endometrial). The sensitivity of conventional Pap smear for endometrial carcinoma is 40 to 55 percent; the sensitivity of liquid-based preparations is higher at 60 to 65 percent [<a href="#rid5">5-7</a>].</p><p>The diagnostic evaluation of patients with abnormal cervical cytology, which may lead to a diagnosis of endometrial cancer, is reviewed in detail separately. (See  <a class="medical medical_review" href="/d/html/3229.html" rel="external">"Cervical cytology: Evaluation of atypical and malignant glandular cells"</a> and  <a class="medical medical_review" href="/d/html/3205.html" rel="external">"Cervical cancer screening: The cytology and human papillomavirus report", section on 'Benign-appearing endometrial cells'</a>.)</p><p class="headingAnchor" id="H20099170"><span class="h2">Incidental finding on imaging</span><span class="headingEndMark"> — </span>A thickened endometrial lining is sometimes found incidentally on ultrasound, computed tomography (CT), or magnetic resonance imaging performed for another indication (eg, abdominal CT in a patient undergoing diagnostic evaluation of acute diverticulitis).</p><p>The diagnostic evaluation of asymptomatic patients with a thickened endometrium, which may lead to a diagnosis of endometrial cancer, is reviewed in detail separately. (See  <a class="medical medical_review" href="/d/html/3232.html" rel="external">"Overview of the evaluation of the endometrium for malignant or premalignant disease", section on 'Incidental finding on TVUS for another indication'</a>.) </p><p class="headingAnchor" id="H1601978"><span class="h2">Incidental finding after hysterectomy or during abdominopelvic surgery</span><span class="headingEndMark"> — </span>Endometrial carcinoma is sometimes discovered incidentally when hysterectomy is performed for benign disease. To minimize this occurrence and optimize the surgical procedure performed, all patients with AUB undergoing hysterectomy should have endometrial sampling, and the results should be available before surgery.</p><p>In a database study including nearly 230,000 patients who underwent a hysterectomy for benign indications, 0.96 percent (95% CI 0.92-1.00) had occult uterine cancer of which 75 percent were endometrial carcinoma and 22 percent were sarcoma [<a href="#rid8">8</a>]. The risk for occult uterine cancer was low (0.10 percent) in patients 18 to 29 years old and much higher (4.40 percent) in patients ≥75 years old. The risk of occult uterine cancer was significantly associated with race/ethnicity, obesity, comorbidity, personal history of malignancy, and reason for hysterectomy (risk in hysterectomy because of endometriosis, fibroids, postmenopausal bleeding: 0.14, 0.62, and 8.43 percent, respectively).</p><p>If abdominopelvic metastases are encountered intraoperatively, management depends upon the experience of the surgeon. Intraoperative consultation from a gynecologic oncologist should be requested, if available, as staging procedures performed by a gynecologic oncologist appear to lead to better patient outcomes [<a href="#rid9">9</a>]. If a gynecologic oncologist is not available and the surgeon is not experienced in operative management of the cancer (eg, lymphadenectomy), we suggest terminating surgery and arranging for prompt postoperative consultation with a specialist to plan a second procedure. (See  <a class="medical medical_review" href="/d/html/16917.html" rel="external">"Overview of resectable endometrial carcinoma", section on 'Epidemiology'</a>.)</p><p class="headingAnchor" id="H281523"><span class="h1">CLINICAL FINDINGS</span></p><p class="headingAnchor" id="H281532"><span class="h2">Physical examination</span><span class="headingEndMark"> — </span>Pelvic examination is usually normal in patients with early-stage endometrial carcinoma since they do not typically have an enlarged or tender uterus. In more advanced disease, the uterus may be enlarged and/or fixed. </p><p class="headingAnchor" id="H281540"><span class="h2">Laboratory</span><span class="headingEndMark"> — </span>Laboratory results are usually normal, except in patients with substantial abnormal uterine bleeding, who may be anemic.</p><p class="headingAnchor" id="H281548"><span class="h2">Ultrasound</span><span class="headingEndMark"> — </span>In postmenopausal patients, the risk of cancer increases relative to benign disease as the endometrial thickness approaches 20 mm on transvaginal ultrasound (endometrial thickness &lt;4 mm is associated with a low risk of endometrial disease). In premenopausal patients, endometrial thickness does not correlate with risk of cancer. (See  <a class="medical medical_review" href="/d/html/3232.html" rel="external">"Overview of the evaluation of the endometrium for malignant or premalignant disease", section on 'Transvaginal ultrasound'</a>.)</p><p class="headingAnchor" id="H1268005"><span class="h1">DIAGNOSIS</span></p><p class="headingAnchor" id="H3650075185"><span class="h2">Tissue sampling for histopathology</span><span class="headingEndMark"> — </span>Endometrial carcinoma is a histologic diagnosis, based upon characteristic findings on an endometrial biopsy, curettage, or hysterectomy specimen. (See  <a class="medical medical_review" href="/d/html/3192.html" rel="external">"Endometrial cancer: Pathology and classification", section on 'Classification'</a> and  <a class="medical medical_review" href="/d/html/3251.html" rel="external">"Endometrial carcinoma: Staging and surgical treatment", section on 'Staging system'</a>.)</p><p>Blind endometrial biopsy is generally sufficient as the initial diagnostic procedure but is most reliable when at least 50 percent of the endometrium is affected by the disease. The sensitivity for endometrial sampling is 90 percent or higher. Risk factors for false-negative endometrial sampling include a personal history of colorectal cancer, endometrial polyps, and class II obesity (ie, body mass index [BMI] ≥35 kg/m<sup>2</sup>) [<a href="#rid10">10</a>]. A biopsy result of endometrial hyperplasia with atypia (also referred to as endometrial intraepithelial neoplasia [EIN]) may also harbor an underlying endometrial cancer. Hysteroscopy with targeted biopsy is likely to detect focal lesions missed by blind biopsy but requires more skill and is more costly and invasive. These issues are discussed in detail separately. (See  <a class="medical medical_review" href="/d/html/3217.html" rel="external">"Endometrial hyperplasia: Clinical features, diagnosis, and differential diagnosis", section on 'Natural history'</a> and  <a class="medical medical_review" href="/d/html/3254.html" rel="external">"Endometrial sampling procedures"</a>.)</p><p>Dilation and curettage (D&amp;C), with or without hysteroscopy, is a reasonable initial procedure in some patients, such as those who cannot tolerate an office biopsy or in whom the office procedure is unsuccessful, those with heavy bleeding (D&amp;C is both a diagnostic and therapeutic procedure), and those at very high risk of endometrial cancer (eg, patients with Lynch syndrome). </p><p class="headingAnchor" id="H282567"><span class="h2">Approach to patients with nondiagnostic histopathology</span><span class="headingEndMark"> — </span>In patients in whom endometrial carcinoma is suspected but blind endometrial biopsy shows insufficient endometrial cells for diagnosis, we may repeat the office biopsy but often move on to hysteroscopy and D&amp;C as the next step. Cervical stenosis, a common cause of an unsuccessful biopsy, can be managed with preprocedure cervical preparation or dilation. Ultrasound guidance may be useful to aid endometrial sampling as well. (See  <a class="medical medical_review" href="/d/html/3254.html" rel="external">"Endometrial sampling procedures", section on 'Cervical preparation and dilation'</a>.)</p><p class="headingAnchor" id="H1555051433"><span class="h2">Approach to selected patients with benign histopathology</span><span class="headingEndMark"> — </span>In patients in whom endometrial carcinoma is suspected because of persistent or recurrent abnormal uterine bleeding despite endometrial sampling with benign findings, further evaluation for cancer is required if another etiology for the bleeding was not established. In our practice, we reevaluate such cases after three to six months. Transvaginal ultrasound, sonohysterography, or diagnostic hysteroscopy are performed to exclude structural lesions (leiomyomas, endometrial polyp). (See  <a class="medical medical_review" href="/d/html/3263.html" rel="external">"Abnormal uterine bleeding in nonpregnant reproductive-age patients: Terminology, evaluation, and approach to diagnosis"</a>.)</p><p>In addition, it is essential to repeat endometrial sampling to exclude endometrial hyperplasia or carcinoma, especially in patients with risk factors for malignancy. Reported rates of endometrial neoplasia in patients evaluated for persistent or recurrent postmenopausal bleeding vary widely, from 4 to 21 percent [<a href="#rid11">11,12</a>]. </p><p class="headingAnchor" id="H282601"><span class="h1">POST-DIAGNOSTIC MANAGEMENT</span></p><p class="headingAnchor" id="H4153311298"><span class="h2">Postmenopausal patients not on hormone therapy</span><span class="headingEndMark"> — </span>Development of endometrial carcinoma in postmenopausal patients requires assessment of endogenous and exogenous sources of estrogen since unopposed estrogen is a risk factor for the disease. In the absence of common sources of estrogen (eg, estrogen therapy, obesity, selective estrogenic receptor modulators, or some herbs), the possibility of an estrogen-producing tumor (eg, sex cord-stromal) should be considered, and a pelvic ultrasound or other imaging study is appropriate to assess for an adnexal mass.</p><p class="headingAnchor" id="H3027976153"><span class="h2">Testing for Lynch syndrome</span><span class="headingEndMark"> — </span>Lynch syndrome is a genetic syndrome that includes increased risk for endometrial cancer. The National Comprehensive Cancer Network recommends universal mismatch repair protein testing or microsatellite instability testing of endometrial carcinomas. The American College of Obstetricians and Gynecologists and the Society of Gynecologic Oncology concur with this strategy for genetic assessment for Lynch syndrome in patients diagnosed with endometrial cancer but also attempt to identify at-risk patients based on a personal or family history of Lynch syndrome-associated cancers [<a href="#rid13">13-16</a>]. Although lower uterine segment tumors account for a small proportion of Lynch-associated endometrial cancers, patients with Lynch syndrome have a higher proportion of tumors in this location than other endometrial cancer patients; therefore, a finding of tumor at this site should also prompt risk assessment for Lynch syndrome [<a href="#rid17">17</a>].</p><p>Testing for Lynch syndrome based on history and/or immunohistochemistry of the uterine tumor for loss of the four mismatch repair proteins (MLH1, MSH2, MSH6, and PMS2) is discussed in detail separately. Multiple patterns have been detected, including deficiencies of both MLH1 and PMS2, both MSH6 and PMS2, isolated MSH6 loss, and isolated MSH2 loss. (See  <a class="medical medical_review" href="/d/html/2605.html" rel="external">"Lynch syndrome (hereditary nonpolyposis colorectal cancer): Clinical manifestations and diagnosis", section on 'Identification of individuals at risk for Lynch syndrome'</a>.)</p><p class="headingAnchor" id="H383882"><span class="h2">Staging and treatment</span><span class="headingEndMark"> — </span>Patients with endometrial carcinoma should undergo staging and treatment, as appropriate.</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/16917.html" rel="external">"Overview of resectable endometrial carcinoma"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/3251.html" rel="external">"Endometrial carcinoma: Staging and surgical treatment"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/3223.html" rel="external">"Treatment of low-risk endometrial cancer"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/16741.html" rel="external">"Adjuvant treatment of intermediate-risk endometrial cancer"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/16721.html" rel="external">"Adjuvant treatment of high-risk endometrial cancers"</a>.)</p><p></p><p>It should be noted that an endometrial tumor may be undergraded when grading is based on sampling procedures rather than hysterectomy [<a href="#rid18">18,19</a>]. A higher grade may be assigned in as many as 30 percent of cases when the hysterectomy specimen is reviewed. The grade assigned by the endometrial sample alone is important mainly for patients who are incompletely surgically staged or inoperable.</p><p class="headingAnchor" id="H2431767049"><span class="h1">PROGNOSIS</span><span class="headingEndMark"> — </span>The prognosis of endometrial carcinoma is determined primarily by disease stage, grade, and histology  (<a class="graphic graphic_table graphicRef141918" href="/d/graphic/141918.html" rel="external">table 2</a> and <a class="graphic graphic_table graphicRef141963" href="/d/graphic/141963.html" rel="external">table 3</a>) [<a href="#rid20">20</a>]. Most patients with endometrial carcinoma have a favorable prognosis since the majority of patients have endometrioid histology and present with early-stage disease. Survival rates by stage are presented in the graphic  (<a class="graphic graphic_figure graphicRef141351" href="/d/graphic/141351.html" rel="external">figure 1</a>).</p><p>Prognostic factors, including molecular prognostic factors, are discussed in detail separately. (See  <a class="medical medical_review" href="/d/html/16917.html" rel="external">"Overview of resectable endometrial carcinoma", section on 'Prognostic factors'</a>.)</p><p class="headingAnchor" id="H1268037"><span class="h1">SCREENING</span></p><p class="headingAnchor" id="H2919514156"><span class="h2">General recommendations</span><span class="headingEndMark"> — </span>In most patients, including those on <a class="drug drug_general" data-topicid="9972" href="/d/drug information/9972.html" rel="external">tamoxifen</a> without vaginal bleeding, we suggest not screening for endometrial carcinoma with imaging, tissue sampling, or cervical cytology as no high-quality data support the efficacy of such screening for reducing endometrial cancer mortality (all patients should be asked about and told to report abnormal uterine bleeding [AUB]). However, patients with Lynch syndrome (hereditary nonpolyposis colon cancer) have a markedly increased risk of endometrial cancer; thus, such patients should be counseled about screening and risk-reducing hysterectomy. (See <a class="local">'Patients with Lynch syndrome'</a> below.)</p><p>Our recommendation is consistent with advice from the American Cancer Society, which suggests informing patients at average or increased risk of developing endometrial cancer (except those with Lynch syndrome) about their risks of developing the disease, educating them about its symptoms (especially any unexpected bleeding) at the onset of menopause, and strongly encouraging them to report such symptoms to their health care provider promptly [<a href="#rid21">21</a>].</p><p>Endometrial carcinoma has several characteristics that inform the recommendation against routine screening. As noted above, 75 to 90 percent of patients with endometrial carcinoma are symptomatic (ie, they present with AUB) [<a href="#rid1">1-3</a>]. The presence of a common, bothersome symptom when the disease is often still confined to the uterus and the availability of effective therapy results in high survival rates without screening.</p><p>Furthermore, no noninvasive test for endometrial cancer is sufficiently sensitive and specific for screening. The sensitivity of conventional Pap smear for endometrial carcinoma is 40 to 55 percent, and the sensitivity of liquid-based preparations is 60 to 65 percent [<a href="#rid5">5-7</a>]. The thickness of the endometrium on transvaginal sonography is a sensitive test for detecting endometrial cancer in postmenopausal patients; however, sensitivity is estimated to be 20 percent lower in asymptomatic compared with symptomatic patients, and specificity is low (the false-positive rate is high); thus, many patients would end up needing an endometrial biopsy. The use of serum biomarkers or epigenetic testing for endometrial cancer is under investigation [<a href="#rid22">22-24</a>]. Endometrial biopsy is a sensitive and specific test, but it is invasive and uncomfortable. (See  <a class="medical medical_review" href="/d/html/3232.html" rel="external">"Overview of the evaluation of the endometrium for malignant or premalignant disease", section on 'Transvaginal ultrasound'</a>.)</p><p class="headingAnchor" id="H282996"><span class="h2">Patients with Lynch syndrome</span><span class="headingEndMark"> — </span>Patients with Lynch syndrome have a lifetime risk of endometrial cancer of 13 to 71 percent, compared with 3 percent in the general population. Strategies for screening and prevention of endometrial cancer in these patients include endometrial sampling and risk-reducing hysterectomy. Screening for endometrial cancer in patients with Lynch syndrome is discussed separately. (See  <a class="medical medical_review" href="/d/html/3224.html" rel="external">"Lynch syndrome (hereditary nonpolyposis colorectal cancer): Screening and prevention of endometrial and ovarian cancer"</a>.)</p><p class="headingAnchor" id="H8895748"><span class="h2">Patients with Cowden syndrome</span><span class="headingEndMark"> — </span>Cowden syndrome is a rare autosomal dominant syndrome that derives from a mutation in the <em>PTEN</em> tumor suppressor gene. Patients with Cowden syndrome have a lifetime risk of endometrial cancer of 13 to 28 percent [<a href="#rid25">25-28</a>]. There are no established guidelines for endometrial screening or prevention for Cowden syndrome [<a href="#rid29">29</a>]. Potential strategies include endometrial sampling and risk-reducing hysterectomy on completion of childbearing, similar to Lynch syndrome.</p><p class="headingAnchor" id="H4281578688"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/d/html/121144.html" rel="external">"Society guideline links: Uterine cancer"</a>.)</p><p class="headingAnchor" id="H1267671"><span class="h1">INFORMATION FOR PATIENTS</span><span class="headingEndMark"> — </span>UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5<sup>th</sup> to 6<sup>th</sup> grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10<sup>th</sup> to 12<sup>th</sup> grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.</p><p>Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient info" and the keyword(s) of interest.) </p><p class="bulletIndent1"><span class="glyph">●</span>Basics topics (see  <a class="medical medical_basics" href="/d/html/15422.html" rel="external">"Patient education: Uterine cancer (The Basics)"</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Beyond the Basics topics (see  <a class="medical medical_patient" href="/d/html/866.html" rel="external">"Patient education: Endometrial cancer diagnosis, staging, and surgical treatment (Beyond the Basics)"</a> and  <a class="medical medical_patient" href="/d/html/871.html" rel="external">"Patient education: Endometrial cancer treatment after surgery (Beyond the Basics)"</a>)</p><p></p><p class="headingAnchor" id="H1267679"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Clinical presentation</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Endometrial carcinoma typically presents with abnormal uterine bleeding (AUB). Other presentations include abnormal cervical cytology findings on cervical cancer screening, abnormal findings on imaging, or discovered incidentally when hysterectomy is performed for benign disease. (See <a class="local">'Clinical presentation'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>While approximately 91 percent of postmenopausal patients with endometrial cancer will present with AUB, the overall risk of endometrial cancer among postmenopausal patients with AUB is approximately 9 percent; estimates vary by use of hormone therapy and geographic region. (See <a class="local">'Abnormal uterine bleeding'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Clinical findings</strong> – Pelvic examination is usually normal in patients with early-stage disease. In more advanced disease, the uterus may be enlarged and/or fixed in the pelvis. In postmenopausal patients, uterine imaging may show a thickened endometrium. (See <a class="local">'Clinical findings'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Diagnosis</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Endometrial carcinoma is a histologic diagnosis based upon the results of evaluation of an endometrial biopsy, curettage sample, or hysterectomy specimen. (See <a class="local">'Tissue sampling for histopathology'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>In patients with AUB in whom endometrial carcinoma is suspected but blind endometrial biopsy showed insufficient endometrial cells for diagnosis, we suggest hysteroscopy and dilation and curettage as the next step in the diagnostic evaluation. (See <a class="local">'Approach to patients with nondiagnostic histopathology'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>In patients with persistent or recurrent AUB and benign findings on initial endometrial sampling, further evaluation for cancer is required if another etiology for the bleeding was not established. In our practice, we reevaluate these patients after three to six months. Transvaginal ultrasound, sonohysterography, or diagnostic hysteroscopy is performed to exclude structural lesions (leiomyomas, endometrial polyp). In addition, it is essential to repeat endometrial sampling to exclude endometrial hyperplasia or carcinoma, especially in patients with risk factors for malignancy. Reported rates of endometrial neoplasia in patients evaluated for persistent or recurrent postmenopausal bleeding vary widely, from 4 to 21 percent. (See <a class="local">'Approach to selected patients with benign histopathology'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Sources of estrogen</strong> – In postmenopausal patients, development of endometrial carcinoma requires assessment of endogenous and exogenous sources of estrogen. In the absence of common sources of estrogen (eg, estrogen therapy, obesity, selective estrogenic receptor modulators, or some herbs), such patients should be evaluated with pelvic ultrasound or other imaging for an adnexal mass, which could be an estrogen-producing sex cord-stromal tumor of the ovary. (See <a class="local">'Postmenopausal patients not on hormone therapy'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Prognosis</strong> – Most patients with endometrial carcinoma have a favorable prognosis  (<a class="graphic graphic_figure graphicRef141351" href="/d/graphic/141351.html" rel="external">figure 1</a>). Prognosis is determined primarily by disease stage, grade, histology, and molecular classification (if known)  (<a class="graphic graphic_table graphicRef141918" href="/d/graphic/141918.html" rel="external">table 2</a> and <a class="graphic graphic_table graphicRef141963" href="/d/graphic/141963.html" rel="external">table 3</a>). (See <a class="local">'Prognosis'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Screening</strong> – For most patients, we suggest <strong>not</strong> performing screening tests (eg, imaging, tissue sampling, cervical cytology) for endometrial carcinoma (<a class="grade" href="https://medilib.ir/uptodate/show/grade_6" rel="external">Grade 2C</a>); all patients should be asked about and told to report AUB. The exception is patients with Lynch syndrome (hereditary nonpolyposis colorectal cancer) and Cowden syndrome who have a lifetime risk of endometrial cancer between 13 and 71 percent compared with 3 percent in the general population. Strategies for screening and prevention of endometrial cancer in these patients include endometrial sampling and risk-reducing hysterectomy. (See <a class="local">'Screening'</a> above and <a class="local">'Patients with Lynch syndrome'</a> above and <a class="local">'Patients with Cowden syndrome'</a> above.)</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">American College of Obstetricians and Gynecologists. ACOG practice bulletin, clinical management guidelines for obstetrician-gynecologists, number 65, August 2005: management of endometrial cancer. Obstet Gynecol 2005; 106:413.</a></li><li><a class="nounderline abstract_t">Kimura T, Kamiura S, Yamamoto T, et al. Abnormal uterine bleeding and prognosis of endometrial cancer. Int J Gynaecol Obstet 2004; 85:145.</a></li><li><a class="nounderline abstract_t">Seebacher V, Schmid M, Polterauer S, et al. The presence of postmenopausal bleeding as prognostic parameter in patients with endometrial cancer: a retrospective multi-center study. BMC Cancer 2009; 9:460.</a></li><li><a class="nounderline abstract_t">Clarke MA, Long BJ, Del Mar Morillo A, et al. Association of Endometrial Cancer Risk With Postmenopausal Bleeding in Women: A Systematic Review and Meta-analysis. JAMA Intern Med 2018; 178:1210.</a></li><li><a class="nounderline abstract_t">Guidos BJ, Selvaggi SM. Detection of endometrial adenocarcinoma with the ThinPrep Pap test. Diagn Cytopathol 2000; 23:260.</a></li><li><a class="nounderline abstract_t">Schorge JO, Hossein Saboorian M, Hynan L, Ashfaq R. ThinPrep detection of cervical and endometrial adenocarcinoma: a retrospective cohort study. Cancer 2002; 96:338.</a></li><li><a class="nounderline abstract_t">Gu M, Shi W, Barakat RR, et al. Pap smears in women with endometrial carcinoma. Acta Cytol 2001; 45:555.</a></li><li><a class="nounderline abstract_t">Desai VB, Wright JD, Gross CP, et al. Prevalence, characteristics, and risk factors of occult uterine cancer in presumed benign hysterectomy. Am J Obstet Gynecol 2019; 221:39.e1.</a></li><li><a class="nounderline abstract_t">Vernooij F, Heintz P, Witteveen E, van der Graaf Y. The outcomes of ovarian cancer treatment are better when provided by gynecologic oncologists and in specialized hospitals: a systematic review. Gynecol Oncol 2007; 105:801.</a></li><li><a class="nounderline abstract_t">Torres ML, Weaver AL, Kumar S, et al. Risk factors for developing endometrial cancer after benign endometrial sampling. Obstet Gynecol 2012; 120:998.</a></li><li><a class="nounderline abstract_t">Twu NF, Chen SS. Five-year follow-up of patients with recurrent postmenopausal bleeding. Zhonghua Yi Xue Za Zhi (Taipei) 2000; 63:628.</a></li><li><a class="nounderline abstract_t">Ronghe R, Gaudoin M. Women with recurrent postmenopausal bleeding should be re-investigated but are not more likely to have endometrial cancer. Menopause Int 2010; 16:9.</a></li><li><a class="nounderline abstract_t">Randall LM, Pothuri B, Swisher EM, et al. Multi-disciplinary summit on genetics services for women with gynecologic cancers: A Society of Gynecologic Oncology White Paper. Gynecol Oncol 2017; 146:217.</a></li><li><a class="nounderline abstract_t">Lancaster JM, Powell CB, Chen LM, et al. Society of Gynecologic Oncology statement on risk assessment for inherited gynecologic cancer predispositions. Gynecol Oncol 2015; 136:3.</a></li><li><a class="nounderline abstract_t">ACOG Practice Bulletin No. 147: Lynch syndrome. Obstet Gynecol 2014; 124:1042.</a></li><li class="breakAll">https://www.nccn.org/professionals/physician_gls/default.aspx#genetics_colon (Accessed on January 17, 2018).</li><li><a class="nounderline abstract_t">Westin SN, Lacour RA, Urbauer DL, et al. Carcinoma of the lower uterine segment: a newly described association with Lynch syndrome. J Clin Oncol 2008; 26:5965.</a></li><li><a class="nounderline abstract_t">Larson DM, Johnson KK, Broste SK, et al. Comparison of D&amp;C and office endometrial biopsy in predicting final histopathologic grade in endometrial cancer. Obstet Gynecol 1995; 86:38.</a></li><li><a class="nounderline abstract_t">Frumovitz M, Singh DK, Meyer L, et al. Predictors of final histology in patients with endometrial cancer. Gynecol Oncol 2004; 95:463.</a></li><li><a class="nounderline abstract_t">Berek JS, Matias-Guiu X, Creutzberg C, et al. FIGO staging of endometrial cancer: 2023. Int J Gynaecol Obstet 2023; 162:383.</a></li><li><a class="nounderline abstract_t">Dash RC, Doud LG. Correlation of pap smear abnormalities in endometrial adenocarcinomas (Abstract). Acta Cytol 2001; 45:835.</a></li><li><a class="nounderline abstract_t">Herzog C, Marín F, Jones A, et al. A Simple Cervicovaginal Epigenetic Test for Screening and Rapid Triage of Women With Suspected Endometrial Cancer: Validation in Several Cohort and Case/Control Sets. J Clin Oncol 2022; 40:3828.</a></li><li><a class="nounderline abstract_t">Tarney CM, Wang G, Bateman NW, et al. Biomarker panel for early detection of endometrial cancer in the Prostate, Lung, Colorectal, and Ovarian cancer screening trial. Am J Obstet Gynecol 2019; 221:472.e1.</a></li><li><a class="nounderline abstract_t">Dottino JA, Zhang Q, Loose DS, et al. Endometrial biomarkers in premenopausal women with obesity: an at-risk cohort. Am J Obstet Gynecol 2021; 224:278.e1.</a></li><li><a class="nounderline abstract_t">Heald B, Mester J, Rybicki L, et al. Frequent gastrointestinal polyps and colorectal adenocarcinomas in a prospective series of PTEN mutation carriers. Gastroenterology 2010; 139:1927.</a></li><li><a class="nounderline abstract_t">Riegert-Johnson DL, Gleeson FC, Roberts M, et al. Cancer and Lhermitte-Duclos disease are common in Cowden syndrome patients. Hered Cancer Clin Pract 2010; 8:6.</a></li><li><a class="nounderline abstract_t">Pilarski R, Stephens JA, Noss R, et al. Predicting PTEN mutations: an evaluation of Cowden syndrome and Bannayan-Riley-Ruvalcaba syndrome clinical features. J Med Genet 2011; 48:505.</a></li><li><a class="nounderline abstract_t">Tan MH, Mester JL, Ngeow J, et al. Lifetime cancer risks in individuals with germline PTEN mutations. Clin Cancer Res 2012; 18:400.</a></li><li class="breakAll">http://www.nccn.org/professionals/physician_gls/pdf/genetics_screening.pdf (Accessed on January 18, 2012).</li></ol></div><div id="topicVersionRevision">Topic 16924 Version 37.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16055605" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : ACOG practice bulletin, clinical management guidelines for obstetrician-gynecologists, number 65, August 2005: management of endometrial cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15099776" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Abnormal uterine bleeding and prognosis of endometrial cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20028502" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : The presence of postmenopausal bleeding as prognostic parameter in patients with endometrial cancer: a retrospective multi-center study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30083701" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Association of Endometrial Cancer Risk With Postmenopausal Bleeding in Women: A Systematic Review and Meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11002368" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Detection of endometrial adenocarcinoma with the ThinPrep Pap test.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12478681" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : ThinPrep detection of cervical and endometrial adenocarcinoma: a retrospective cohort study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11480718" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Pap smears in women with endometrial carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30853364" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Prevalence, characteristics, and risk factors of occult uterine cancer in presumed benign hysterectomy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17433422" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : The outcomes of ovarian cancer treatment are better when provided by gynecologic oncologists and in specialized hospitals: a systematic review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23090515" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Risk factors for developing endometrial cancer after benign endometrial sampling.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10969449" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Five-year follow-up of patients with recurrent postmenopausal bleeding.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20424280" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Women with recurrent postmenopausal bleeding should be re-investigated but are not more likely to have endometrial cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28596016" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Multi-disciplinary summit on genetics services for women with gynecologic cancers: A Society of Gynecologic Oncology White Paper.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25238946" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Society of Gynecologic Oncology statement on risk assessment for inherited gynecologic cancer predispositions.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25437740" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : ACOG Practice Bulletin No. 147: Lynch syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25437740" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : ACOG Practice Bulletin No. 147: Lynch syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19001318" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Carcinoma of the lower uterine segment: a newly described association with Lynch syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7784020" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Comparison of D&amp;C and office endometrial biopsy in predicting final histopathologic grade in endometrial cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15581947" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Predictors of final histology in patients with endometrial cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37337978" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : FIGO staging of endometrial cancer: 2023.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Correlation of pap smear abnormalities in endometrial adenocarcinomas (Abstract)</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36001862" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : A Simple Cervicovaginal Epigenetic Test for Screening and Rapid Triage of Women With Suspected Endometrial Cancer: Validation in Several Cohort and Case/Control Sets.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31279844" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Biomarker panel for early detection of endometrial cancer in the Prostate, Lung, Colorectal, and Ovarian cancer screening trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32835719" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Endometrial biomarkers in premenopausal women with obesity: an at-risk cohort.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20600018" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Frequent gastrointestinal polyps and colorectal adenocarcinomas in a prospective series of PTEN mutation carriers.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20565722" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Cancer and Lhermitte-Duclos disease are common in Cowden syndrome patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21659347" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Predicting PTEN mutations: an evaluation of Cowden syndrome and Bannayan-Riley-Ruvalcaba syndrome clinical features.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22252256" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Lifetime cancer risks in individuals with germline PTEN mutations.</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
